Digital Angel Corporation (“Digital Angel” or the “Company”) (OTC
Markets: DIGA), a provider of implantable medical device identification
and radiation dose measurement technologies, following its recent share
exchange with VeriTeQ Acquisition Corporation (“VeriTeQ”), announced
today that it will host a conference call on Monday, October 21, 2013,
at 10 a.m. ET to update investors on recent corporate events.
Interested participants should call (800) 219-3192 within the United
States or (617) 597-5412 internationally. Please use passcode 96570958#.
For those unable to participate in the conference call, a replay will be
available from October 21 at 9 a.m. ET to October 29 at 11:59 p.m. ET.
For the replay, dial (888) 286-8010 within the United States or (617)
801-6888 internationally, using access code 86095249. For those unable
to participate in the conference call, a digitized replay will be
available 24 hours following the conference call on the Company’s
website at www.veriteqcorp.com.
About Digital Angel and VeriTeQ
Digital Angel, through its VeriTeQ wholly-owned subsidiary, develops
innovative, proprietary RFID technologies for implantable medical device
identification, and dosimeter technologies for use in radiation therapy
treatment. VeriTeQ offers the world's first FDA cleared RFID microchip
technology that can be used to identify implantable medical devices, in
vivo, on demand, at the point of care. VeriTeQ's dosimeters provide
patient safety mechanisms while measuring and recording the dose of
radiation delivered to a patient in real time. For more information on
VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future expectations
constitute "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements involve
risks and uncertainties and are subject to change at any time, and our
actual results could differ materially from expected results. These
risks and uncertainties include, without limitation, the ability to
promptly and effectively integrate the businesses of Digital Angel and
VeriTeQ; VeriTeQ’s ability to target the UDI sector and medical device
manufacturers; VeriTeQ’s ability to raise capital; as well as other
risks. Additional information about these and other factors may be
described in future filings with the Securities and Exchange Commission
The Company undertakes no obligation to update or release any revisions
to these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Copyright Business Wire 2013